Regeneron’s melanoma flop now has lawyers sniffing around

The trial miss wasn’t the end of it

Regeneron’s weekend headache just turned into a fresh legal one. SueWallSt says it’s investigating whether Regeneron Pharmaceuticals may have violated securities laws after executives talked up the outlook for a Phase 3 melanoma study that later failed to hit its primary endpoint.

The stock didn’t exactly shrug this off. Shares dropped more than 10% when the market opened on May 18th, which is the financial-market version of tripping on the front steps and then realizing the whole neighborhood saw it.

Why investors care

This kind of announcement matters for two reasons:

• First, the science itself: the company’s Fianlimab + Libtayo combo missed versus Merck’s Keytruda in first-line unresectable or metastatic melanoma.
• Second, the legal overhang: if investors think management was overly sunny before the data came out, the stock can get dragged into a long, expensive lawsuit carousel.

Big picture

Clinical setbacks are bad enough on their own. Add a securities investigation, and suddenly you’ve got a story that can weigh on sentiment long after the lab-coat drama fades.